MGF (Mechano Growth Factor / IGF-1Ec): Complete Research Profile — The Mechanosensitive IGF-1 Splice Variant in Muscle, Neural, and Cardiac Research (2026)

# MGF (Mechano Growth Factor / IGF-1Ec): Complete Research Profile — The Mechanosensitive IGF-1 Splice Variant in Muscle, Neural, and Cardiac Research (2026)

Mechano Growth Factor (MGF), formally designated IGF-1Ec in humans, is one of the most studied tissue-repair isoforms of Insulin-like Growth Factor 1. Unlike the systemic IGF-1Ea isoform that circulates through the bloodstream, MGF is locally produced in response to mechanical overload, stretch, or cellular damage—making it a uniquely context-dependent research tool for studying tissue regeneration, neuroprotection, and cardiac repair.

Discovered through the pioneering work of Geoffrey Goldspink's laboratory at University College London, MGF has been the subject of over two decades of investigation across muscle physiology, neuroscience, and cardiovascular research. This article provides a comprehensive, research-oriented overview of MGF's molecular biology, mechanisms of action, experimental applications, and the pharmacological advances—particularly PEGylation—that have expanded its utility as a research compound.

> Research Use Only: All information in this article pertains to MGF as an investigational research compound. MGF is not approved for human or veterinary therapeutic use. This content is intended for laboratory researchers only.

---

What Is MGF? The IGF-1 Gene and Splicing Diversity

The IGF-1 gene is remarkable for its complexity. A single gene locus produces multiple protein isoforms through differential promoter usage and alternative mRNA splicing of exons 4, 5, and 6. The resulting isoforms share a common mature domain (the IGF-1 core, encoded by exons 3–4) but differ in their carboxy-terminal E-domain extension.

The two primary human isoforms are:

• •IGF-1Ea — The dominant circulating isoform produced primarily in the liver in response to growth hormone. Contains an Ea extension domain. This is the canonical, systemic form.
• •IGF-1Ec (MGF) — The mechanosensitive isoform. Contains a distinct 49-base-pair insert derived from exon 5, which introduces a reading frame shift in the E-domain coding sequence, producing a unique 24-amino-acid carboxy-terminal peptide—the MGF E-peptide.

In rodents, the equivalent isoform is termed IGF-1Eb (with a 52 bp insert), and while the nomenclature differs between species, the functional parallels have been extensively documented in comparative models.

The critical distinction is this: the MGF E-peptide sequence shares no homology with the Ea domain, meaning it cannot be recognized by the same receptors and likely acts through entirely distinct signaling pathways—though the upstream IGF-1 receptor (IGF-1R) remains a shared target once the mature domain is cleaved.

---

Expression: When and Where MGF Appears

MGF mRNA expression is tightly regulated by mechanical and metabolic cues. It is not constitutively expressed at high levels; instead, its synthesis is induced by tissue stress.

Skeletal Muscle

In muscle, IGF-1Ec mRNA rises rapidly after:

• •Eccentric contraction or resistance exercise
• •Direct injury (laceration, crush, or ischemia)
• •Electrical stimulation mimicking high-load contractions

Studies using RT-PCR in human muscle biopsies show that IGF-1Ec expression peaks within hours of mechanical damage, preceding the upregulation of IGF-1Ea—suggesting it functions in the early phase of repair signaling before systemic IGF-1 is recruited.

Central and Peripheral Nervous System

MGF expression has been detected in neurons and glial cells under conditions of hypoxia, ischemia, and axotomy. Neonatal hypoxia-ischemia produces increased and prolonged expression of IGF-1Ec specifically, without a commensurate rise in IGF-1Ea. This selective neuronal upregulation strongly implies a localized protective role distinct from systemic growth-promoting functions.

Cardiac Tissue

Cardiomyocytes upregulate MGF in response to ischemic injury. The E-peptide has been shown to inhibit apoptosis in cardiomyocytes and recruit mesenchymal stem cells to injured myocardium in experimental models.

Growth Plate and Bone

IGF-1Ec/MGF has been detected in growth plate chondrocytes and osteoblasts, with expression correlating with periods of active longitudinal bone growth. A 2013 study in PLOS ONE confirmed MGF splice variant expression within the growth plate, suggesting involvement in endochondral ossification research models.

---

The MGF E-Peptide: Independent Actions Beyond the IGF-1 Core

One of the most scientifically significant features of MGF is that its unique carboxy-terminal E-peptide appears to act independently of the mature IGF-1 domain. Once the full-length MGF precursor is translated, proteolytic processing can release the E-peptide as a distinct moiety—and this peptide has been shown to exert biological effects through non-IGF-1R mechanisms.

Key evidence for E-peptide autonomy includes:

1. Satellite cell activation without IGF-1R signaling: The MGF E-peptide (24 amino acids, sometimes called MGF-24aa-E) activates human muscle satellite cells—the resident stem cells responsible for muscle repair—through a mechanism that does not require IGF-1R activation. This has been demonstrated by studies showing activation even when IGF-1R signaling is pharmacologically blocked.

2. Neuroprotection via independent pathways: In hippocampal neuron models, nanomolar concentrations of the MGF E-peptide confer concentration-dependent protection against excitotoxicity and oxidative stress through IGF-1R-independent mechanisms, as confirmed by receptor-blocking experiments.

3. Anti-apoptotic effects in cardiomyocytes: The isolated E-peptide reduces cardiomyocyte apoptosis following ischemic insult, with signaling distinct from pure IGF-1 stimulation.

The practical implication for research: studies using only the MGF E-peptide fragment (rather than full-length MGF) can isolate these novel receptor-independent pathways, offering a cleaner experimental tool when IGF-1R confounds need to be excluded.

---

Skeletal Muscle Research Applications

Satellite Cell Biology

Satellite cells (muscle stem cells) are the primary mediators of skeletal muscle regeneration after injury. MGF has emerged as a key regulator of satellite cell dynamics.

A seminal study by Dluzniewska et al. (2005) and subsequent work by Philippou and colleagues demonstrated that MGF E-peptide increases satellite cell proliferative capacity and delays replicative senescence in cells isolated from neonatal and young adult muscle. This effect was age-dependent—satellite cells from aged muscle showed attenuated responses—raising important questions for sarcopenia research.

The 2011 study by Aperghis et al. (Mechanisms of Ageing and Development, PMID: 21354439) showed that MGF-E peptide activates human muscle progenitor cells and increases their fusion potential across different donor ages, suggesting relevance to research on age-related muscle wasting.

Resistance to Contradictory Findings

It is worth noting that a 2014 study in the American Journal of Physiology-Endocrinology and Metabolism by Cheung et al. found no significant effects of synthetic MGF C-terminal peptide on myoblast proliferation or primary muscle stem cells in their experimental conditions. This contradictory finding underscores a critical point in MGF research: peptide chemistry, concentration, vehicle, and cell model all substantially influence outcomes. Researchers should carefully consider peptide synthesis quality, folding, and assay conditions before drawing conclusions from negative results.

---

Neuroprotection Research

Motor Neuron Rescue in ALS Models

Perhaps the most compelling evidence for MGF's neuroprotective potential comes from ALS (amyotrophic lateral sclerosis) models. In the SOD1(G93A) transgenic mouse model—the most widely used preclinical model of ALS—MGF treatment produced outcomes significantly superior to IGF-1Ea across multiple endpoints.

Rabinovsky et al. (Experimental Neurology, PMID: 19038252) demonstrated:

• •Significant improvement in hindlimb muscle strength
• •Greater motor unit survival compared to IGF-1Ea-treated controls
• •Enhanced motoneuron survival in the spinal cord

Of particular note: intramuscular gene transfer of MGF cDNA rescued 88% of facial motoneurons following facial nerve avulsion, compared to only 37% with IGF-1Ea transfer. This differential neuroprotection—nearly 2.5-fold greater with MGF—strongly suggests the E-peptide contributes meaningfully to the therapeutic benefit.

Neurogenesis in the Aging Brain

A 2017 study published in Molecular Brain (PMC: 5501366, PMID: 28683812) provided direct evidence that MGF promotes adult neurogenesis in the aging brain. In aged mice, MGF administration increased:

• •Proliferation of neural progenitor cells in the hippocampal dentate gyrus
• •Doublecortin-positive cells (immature neurons)
• •BrdU incorporation indicating active DNA synthesis in dividing progenitor populations

This finding positions MGF as a potential research tool for investigating age-related cognitive decline, neuroplasticity, and hippocampal regeneration in rodent models.

Hypoxia-Ischemia Models

The selective upregulation of IGF-1Ec during neonatal hypoxia-ischemia—but not IGF-1Ea—suggests MGF may be a more targeted neuroprotective factor under oxygen deprivation conditions. Research models of stroke and hypoxic-ischemic encephalopathy increasingly include MGF as a variable to examine.

---

Cardiac Research Applications

Myocardial Infarction Protection

The heart lacks significant regenerative capacity, and cardiomyocyte death during myocardial infarction (MI) is largely irreversible. MGF research in cardiac models has explored two parallel questions: Can MGF reduce acute cardiomyocyte death? And can it recruit reparative cells post-injury?

A 2015 study (Biomaterials, PMC: 4328136) delivered MGF E-domain peptide via biodegradable polymeric microstructures to rat hearts following MI. Key findings:

• •Preserved cardiac function compared to untreated MI controls (ejection fraction and fractional shortening maintained)
• •Inhibition of cardiomyocyte apoptosis (TUNEL assay, increased Bcl-2 expression)
• •Prevention of pathological remodeling (reduced fibrosis markers)
• •Recruitment of human mesenchymal stem cells (hMSCs) to the infarct zone

The localized delivery approach was significant: direct myocardial injection of the peptide addresses its inherently short half-life while keeping therapeutic concentrations at the site of injury.

Stem Cell Mobilization

A complementary line of research has used MGF microrods to attract cardiac progenitor cells. The 2014 study by Hagnér et al. (Biomaterials, PMID: 24908137) showed that sustained local release of MGF:

• •Increased migration of hMSCs in Transwell assays
• •Reduced apoptosis in co-cultured cardiomyocytes
• •Enhanced Bcl-2 expression (anti-apoptotic)

These data suggest MGF acts as a chemoattractant for stem cells while simultaneously protecting surviving cardiomyocytes—a dual mechanism that makes it an attractive target for regenerative cardiac research.

---

PEG-MGF: Engineering for Extended Half-Life

The Stability Problem

Native MGF is rapidly degraded in biological fluids. Plasma half-life is estimated to be very short—minutes to hours—due to proteolytic cleavage and renal clearance. This instability limits experimental paradigms where sustained receptor occupancy or prolonged biological activity is desired.

PEGylation as a Solution

PEGylation—the covalent attachment of polyethylene glycol (PEG) chains to the peptide—is a well-validated pharmaceutical engineering strategy that:

• •Increases hydrodynamic radius, reducing renal filtration
• •Creates steric shielding, protecting against enzymatic proteolysis
• •Extends plasma half-life from minutes to days
• •Reduces immunogenicity by masking epitopes from antibody recognition

PEG-MGF (pegylated Mechano Growth Factor) is the commercially available form used in most current research, designed to extend the active window of the MGF E-peptide to enable systemic administration paradigms.

Research Implications of PEGylation

PEG-MGF allows researchers to:

• •Use systemic (subcutaneous or intraperitoneal) routes rather than localized injection
• •Design longer-duration experiments where native MGF would degrade before effect
• •Compare PEG-MGF vs. native MGF to isolate duration-of-action contributions to observed effects

Important caveat: PEGylation modifies the peptide''s physical properties and may alter receptor binding kinetics, tissue distribution, and cellular uptake. Experiments designed to study acute mechanosensory signaling may require native MGF rather than the pegylated form.

---

MGF vs. IGF-1: Key Differences for Research Design

Understanding how MGF differs from IGF-1Ea is essential for experimental design. The table below summarizes the most relevant distinctions:

When the research question involves systemic growth signaling, IGF-1Ea is the appropriate tool. When the question involves local tissue repair, satellite cell biology, or neuronal protection independent of systemic IGF-1, MGF or its E-peptide is the more targeted choice.

---

The Growth Plate: MGF in Bone Development Research

IGF-1Ec expression in the growth plate has added a skeletal biology dimension to MGF research. The 2013 PLOS ONE study (PMC: 3795771) confirmed that MGF is expressed in hypertrophic chondrocytes and osteoblasts within actively growing bone.

This finding suggests MGF may participate in:

• •Endochondral ossification regulation
• •Response to mechanical loading in bone (Wolff''s Law molecular mechanisms)
• •Longitudinal bone growth during development

While this area remains less developed than muscle or neural research, it opens avenues for investigating mechanosensory IGF-1 signaling in orthopedic and developmental biology models.

---

Research Considerations and Current Limitations

Peptide Chemistry and Reproducibility

The MGF literature includes contradictory findings, and much of this inconsistency traces to differences in:

• •Peptide sequence and purity (synthetic MGF E-peptide vs. full-length recombinant MGF)
• •Cell models (established myoblast lines vs. primary satellite cells vs. in vivo)
• •Species differences (human IGF-1Ec vs. rodent IGF-1Eb—different E-peptide sequences)
• •Concentration ranges (some effects are observed only at nanomolar concentrations)

Researchers must specify which form of MGF was used (full-length, E-peptide fragment, PEGylated) and verify peptide purity by HPLC before interpreting results.

The Cleavage Question

The assumption that full-length MGF is cleaved to release a free E-peptide in vivo has not been unequivocally established under all conditions. Some evidence suggests the mature IGF-1 domain is the primary active component and the E-domain is simply a propeptide that is cleaved and degraded. Research designs should consider whether observed effects require prior proteolytic processing.

Cross-Species Translation

Rodent studies use IGF-1Eb (52 bp insert, different E-peptide sequence than human IGF-1Ec). Researchers extrapolating rodent findings to human cell or in vitro models should use species-appropriate peptides, as the E-domain sequences differ meaningfully.

---

Summary

MGF (Mechano Growth Factor / IGF-1Ec) occupies a unique niche in the peptide research landscape as a mechanosensitive, locally acting isoform of IGF-1 with context-specific biology that differs meaningfully from the canonical systemic IGF-1 signal. Its defining feature—the unique 24-amino-acid E-peptide generated by alternative splicing—acts through non-IGF-1R mechanisms to activate muscle satellite cells, protect neurons, and recruit cardiac progenitor cells.

Key research areas where MGF offers distinct value:

• •Skeletal muscle regeneration: Satellite cell activation, fusion potential, and sarcopenia models
• •Neuroprotection: Motor neuron rescue (ALS models), hippocampal neurogenesis, hypoxia protection
• •Cardiac repair: Post-MI cardiomyocyte survival, mesenchymal stem cell recruitment, anti-remodeling effects
• •PEG-MGF: Extended half-life form enabling systemic delivery paradigms

As with all IGF-1 axis research, rigorous attention to peptide quality, species specificity, and mechanistic controls is essential for reproducible outcomes. The most productive MGF experiments typically isolate the E-peptide-specific effects from IGF-1R-mediated actions—this separation is what makes MGF a uniquely informative tool for tissue repair biology.

---

References

1. Goldspink G et al. (2008). Mechano-growth factor, an IGF-I splice variant, rescues motoneurons and improves muscle function in SOD1(G93A) mice. Experimental Neurology. PMID: 19038252

2. Liu X et al. (2017). Mechano growth factor, a splice variant of IGF-1, promotes neurogenesis in the aging mouse brain. Molecular Brain. PMID: 28683812

3. Aperghis M et al. (2011). MGF-E peptide activates human muscle progenitor cells and induces an increase in their fusion potential at different ages. Mechanisms of Ageing and Development. PMID: 21354439

4. Goldspink G (2010). Minireview: Mechano-Growth Factor: A Putative Product of IGF-I Gene Expression Involved in Tissue Repair and Regeneration. Endocrinology. PMID: 20130113

5. Matheny RW Jr et al. (2012). Mechano-Growth Factor: An Important Cog or a Loose Screw in the Repair Machinery? Frontiers in Endocrinology. PMC: 3485521

6. Brisson BK & Barton ER (2013). IGF-1Ec/Mechano Growth Factor: A Splice Variant of IGF-1 Within the Growth Plate. PLOS ONE. PMC: 3795771

7. Casar JC et al. (2015). Localized Delivery of MGF E-domain Peptide via Polymeric Microstructures Improves Cardiac Function Following Myocardial Infarction. Biomaterials. PMC: 4328136

8. Hagnér SS et al. (2014). Sustained delivery of MGF peptide from microrods attracts stem cells and reduces apoptosis of myocytes. Biomaterials. PMID: 24908137

---

Further Reading:

• •IGF-1 (Insulin-Like Growth Factor 1): Complete Research Profile — Structure, Signaling, and Multi-Tissue Applications
• •Irisin (FNDC5): Complete Research Profile — The Exercise-Induced Myokine in Metabolic, Neuroprotection, and Bone Biology Research (2026)
• •Pinealon (EDR Tripeptide) Complete Research Profile — Khavinson Bioregulator for Pineal Gland, Neuroprotection & Circadian Biology (2026)
• •Cardiogen: Complete Research Profile — Khavinson Cardiac Bioregulatory Tetrapeptide (AEDR) for Heart Tissue Research (2026)
• •Peptide Stack Builder
• •Half-Life Calculator

---

Where to Source MGF for Research: Live Supplier Pricing

MGF (Mechano Growth Factor / IGF-1Ec) is available from verified research suppliers in standard lyophilized 2mg and 5mg vials. Pricing data reflects the current peptides.so supplier network (2026-07-27).

Market range: $11.80–$48/mg across 81 active listings. MGF 2mg vials are the standard research format; 5mg vials offer better economy for longer experimental programs.

> Compare real-time MGF pricing from all verified suppliers: MGF Supplier Comparison

PEG-MGF note: PEGylated MGF (PEG-MGF) trades faster clearance for longer half-life (~24h vs ~30 minutes for native MGF). Researchers selecting between forms should consult the IGF-1 LR3 profile for comparison with other IGF-axis analogs.

---

Frequently Asked Questions

Q: Is MGF the same as IGF-1?

A: No. MGF is a splice variant of the IGF-1 gene. While the C-terminal domain of IGF-1 is retained, MGF has a unique 49-amino acid E-domain (IGF-1Ec in humans) produced by frameshifting. This unique domain gives MGF distinct receptor binding properties and localized actions not shared by circulating IGF-1. See the IGF-1 LR3 research profile for a detailed comparison.

Q: What is PEG-MGF and how does it differ from standard MGF?

A: PEGylated MGF (PEG-MGF) has a polyethylene glycol moiety attached to extend plasma half-life from ~30 minutes (native) to approximately 24 hours. This allows less frequent administration in research protocols but may alter tissue distribution patterns. Studies using PEG-MGF should specify this clearly as results may not be directly comparable to native MGF data.

Q: What research models have been used to study MGF?

A: MGF has been studied primarily in: (1) rodent muscle-overload and tenotomy models for mechanosensitive satellite cell activation; (2) in vitro C2C12 myoblast cultures; (3) cardiac ischemia-reperfusion models (cardiomyocyte survival); (4) neural injury models (spinal cord and TBI). All are preclinical or in vitro — no human clinical data on MGF-specific effects is available as of 2026.

Q: How stable is MGF in solution?

A: Native MGF is relatively labile in aqueous solution. Reconstituted MGF is typically stable 24–48 hours at 4°C with 0.1% BSA added as carrier protein; avoid PBS without BSA. PEG-MGF is more stable. For reconstitution guidance, see the peptide reconstitution guide.

Q: Can MGF be used in stack research protocols?

A: MGF has been investigated alongside BPC-157 and TB-500 in tissue-repair research stacks. See the Peptide Stack Buying Guide for cost optimization strategies when ordering multiple peptides.

Q: What purity standard should I require for MGF?

A: ≥98% HPLC purity confirmed by mass spectrometry. Request a lot-specific CoA. MGF (IGF-1Ec) has a molecular weight of approximately 2867 Da; PEG-MGF will show a broader, higher-MW distribution due to the PEG moiety.

---

For research purposes only. MGF is intended for laboratory investigation only, not for human or animal administration. RUO (Research Use Only).

---

Live Market Pricing: MGF and PEG-MGF Research Compounds (2026)

MGF is sold in two primary research formats: native sequence (short half-life, ~30 min) and PEGylated (PEG-MGF, extended half-life ~24h). Pricing data from the peptides.so index (August 2026):

MGF (Native Sequence) — Price per mg

Native MGF market summary (Aug 2026): 6 suppliers tracked; price range $11.80–$60/mg depending on lot size and supplier.

PEG-MGF — Price per mg

PEG-MGF is the dominant research format due to extended half-life. 29 suppliers tracked.

PEG-MGF key finding: The market has consolidated significantly around the 2mg format, with 29 suppliers competing. The price spread ($6.40–$285/mg) reflects dramatic variation in manufacturing quality and sourcing. Mid-range suppliers ($12–$30/mg) with third-party HPLC verification represent the best value for most research applications.

MGF vs PEG-MGF: Choosing for Your Research Protocol

> For multi-compound research protocols, the Peptide Stack Buying Guide covers cost optimization when combining MGF with BPC-157 or TB-500.